A Phase 3 interventional study of Dara SC and Dara IV in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Completed at 146 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-29.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.
Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 10th largest by enrollment, is one of 12 that started in 2017, is one of 24 in phase 3, and was the 31st registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Eden Biltibo · Sites in United States
Ages 18–70
AbbVie · Sites in United States, Australia, Belgium and 9 more countries
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Peking University People's Hospital · Sites in China
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
By country, each count listing its studies:
daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 84 · Phase 3 25 · Phase 4 4
First in 2008; this study’s year is marked. 12 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 522 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 132 interventional studies. Of the 55 that completed or were terminated, 28 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 132 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
126 studies in Multiple Myeloma by Johnson & Johnson: 13 open now, 33 under way, 12 of them phase 3. Of 82 finished, 33 (40%) have results posted.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 14th largest by enrollment of the 100 interventional ones that give a count, is one of 6 that started in 2017, is one of 35 in phase 3, and was the 74th registered.
Johnson & Johnson’s Multiple Myeloma studies by the year they started, since 1995.
19 of the studies testing daratumumab in Multiple Myeloma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06952478Phase 3CelltrionA Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma | 2027-03-08 |
| NCT04009109Alliance Foundation Trials, LLC.Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | 2026-12 |
| NCT06697483Peking University People's HospitalRisk Stratification and MRD-driven Maintenance for MM After ASCT | 2026-12-31 |
| NCT04991103University of Alabama at BirminghamMinimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) | 2027-01-01 |
| NCT03829371University of Turin, ItalySTUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | 2027-01-03 |
Add all 19 to your calendar (.ics) → With an account.
Among the 132 studies testing daratumumab in Multiple Myeloma, from their registry updates:
Among Johnson & Johnson’s 126 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to show that subcutaneous (SC) administration of daratumumab co-formulated with recombinant human hyaluronidase PH20 (Dara SC) is non-inferior to intravenous (IV) administration of daratumumab (Dara IV) in terms of the overall response rate (ORR) and maximum trough concentration (Ctrough).
The study population will consist of adults diagnosed with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or whose disease is refractory to both a PI and an IMiD. The study consists of 3 phases: a screening phase (up to 28 days), a treatment phase, and a follow-up phase. Efficacy, pharmacokinetics, immunogenicity, biomarkers and safety will be assessed at scheduled time. Follow-up will continue until the end of the data collection period, approximately 24 months after the last participant was randomized or when the median overall survival for both arms has been reached, whichever occurs first. The primary hypotheses is that the ORR and maximum Ctrough for Dara SC 1800 milligram (mg) are not inferior to the ORR and maximum Ctrough, respectively, for Dara IV 16 mg per kilogram (mg/kg) in participants with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or whose disease is refractory to both a PI and an IMiD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documented multiple myeloma as defined by the criteria below:
at Screening as defined by any of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a fixed dose of daratumumab as 1800 milligram (mg) subcutaneously (Dara SC) co-formulated with recombinant human hyaluronidase (rHuPH20) 2000 Unit per milliliter (U/mL), once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study. The duration for each cycle is 4 weeks.
Drug: Dara SC
Participants will receive daratumumab for intravenous infusion (Dara IV) 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks on Day 1 in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study. The duration for each cycle is 4 weeks. For Participants still receiving treatment with Dara-IV at the time of Protocol Amendment 4 the duration of infusion may be shortened to a 90-minute infusion or participants will have the option to switch to Dara 1800 mg subcutaneous (SC) on Day 1 of any cycle, at the discretion of the investigator.
Drug: Dara SC · Drug: Dara IV
Participants will receive a fixed dose of Dara SC as 1800 mg daratumumab with rHuPH20 2000 U/mL, once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
Participants will receive Dara IV 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
Also known as: JNJ-54767414
Overall Response Rate (ORR)
ORR was defined as the percentage of participants who achieved partial response (PR) or better according to International Myeloma Working Group (IMWG) criteria, during or after study treatment. IMWG criteria for PR: greater than or equal to (\>=) 50 percent (%) reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to less than (\<) 200 milligrams (mg)/24 hours, If the serum and urine M-proteins are not measurable, a decrease of \>=50% in the difference between involved and uninvolved free light chain (FLC) levels were required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay was also not measurable, \>=50% reduction in bone marrow plasma cells (PCs) was required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%. In addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas was also required.
Time frame: Up to 1 year 8 months
Maximum Trough Concentration (Ctrough) of Daratumumab
Maximum Ctrough was defined as the serum predose concentration of daratumumab on Cycle 3 Day 1.
Time frame: Predose on Cycle 3 Day 1 (each cycle of 28 days)
Percentage of Participants With Treatment-emergent Infusion-related Reactions (IRR)
Percentage of participants with treatment-emergent infusion-related reactions were reported.
Time frame: Up to 3 years
Progression Free Survival (PFS)
PFS was defined as time from date of randomization to either progression of disease (PD), death due to any cause, whichever occurs first. IMWG criteria for PD: Increase of 25% from lowest response value in any one of the following: Serum M component (absolute increase must be \>=0.5 gram per deciliter (g/dL), Urine M-component (absolute increase must be \>=200 mg/24 hours), Participants without measurable serum and urine Mprotein levels: difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be \>10 milligrams per deciliter (mg/dL), participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow PC% (absolute percentage must be \>=10%), definite development of new bone lesions or soft tissue plasmacytomas or increase in size of bone lesions or tissue plasmacytomas and development of hypercalcemia (serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.
Time frame: Up to 3 years
Percentage of Participants With Very Good Partial Response (VGPR) or Better
VGPR or better was defined as the percentage of participants who achieved VGPR or better (VGPR, complete response (CR) or stringent complete response \[sCR\]), based on computerized algorithm as per IMWG criteria during or after the study treatment. IMWG criteria for VGPR: Serum and urine M-component detectable by immunofixation but not on electrophoresis, or \>=90 percent (%) reduction in serum M-protein plus urine M-protein \<100 milligrams (mg)/24 hours, CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells (PCs) in bone marrow. sCR: CR plus normal FLC ratio, and absence of clonal PCs by immunohistochemistry (IHC), immunofluorescencea or 2- to 4 color flow cytometry.
Time frame: Up to 3 years
Percentage of Participants With Complete Response (Including sCR) or Better
CR or better was defined as percentage of participants with a CR or better (CR or stringent complete response \[sCR\]) based on computerized algorithm as per IMWG criteria. IMWG criteria for CR- negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and \<5% PCs in bone marrow. sCR: CR plus normal FLC ratio, and absence of clonal PCs by IHC, immunofluorescencea or 2- to 4 color flow cytometry.
Time frame: Up to 3 years
Time to Next Therapy
Time to next therapy was defined as the time from randomization to the start of the first subsequent anti-cancer therapy.
Time frame: Up to 3 years
Overall Survival (OS)
OS was defined as the time from the date of randomization to the date of the participant's death due to any cause.
Time frame: Up to 3 years
Patient-Reported Satisfaction With Therapy as Assessed With Cancer Therapy Satisfaction Questionnaire (CTSQ)
Modified-CTSQ contain 9 items (2 items for Thoughts about Cancer Therapy and 7 items in a defined domain of Satisfaction with Therapy) specific to satisfaction with therapy and for comparison of SC and IV administration. Satisfaction with therapy was calculated based on 7-items using 5-point verbal rating scale, where 1= never and 5= always. Scores were averaged and transformed to a 0-100 scale; higher scores represent better health. At least 5 of the 7 items within the Satisfaction with Therapy domain had to be completed to calculate a domain score. No domain score was calculated for Thoughts about Cancer Therapy.
Time frame: Cycle 1 (Days 8,15 and 22), Cycle 2 (Days 1,8,15 and 22), Cycle 3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21 and 22 (Day 1)
Duration of Response
Duration of response was defined as the duration from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease according to the IMWG criteria. PD was defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M-component (absolute increase must be \>= 0.5 g/dL and \>=200 mg/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \> 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.
Time frame: Up to 3 years
Time to Partial Response (PR) or Better
Time to PR or better was defined as the time from randomization until onset of first response of PR or better.
Time frame: Up to 3 years
Time to Very Good Partial Response (VGPR) or Better
Time to VGPR or better was defined as the time from randomization until onset of first VGPR or better.
Time frame: Up to 3 years
Time to Complete Response (CR) or Better
Time to CR or better was defined as the time from randomization until onset of first CR or better.
Time frame: Up to 3 years
| Milestone | Daratumumab IV | Daratumumab SC |
|---|---|---|
| Started | 259 | 263 |
| Treated (safety analysis set) | 258 | 260 |
| Completed | 0 | 0 |
| Not completed | 259 | 263 |
| Withdrew: Death | 129 | 124 |
| Withdrew: Lost to follow-up | 2 | 4 |
| Withdrew: Withdrawal by subject | 10 | 10 |
| Withdrew: Other | 118 | 125 |
ORR was defined as the percentage of participants who achieved partial response (PR) or better according to International Myeloma Working Group (IMWG) criteria, during or after study treatment. IMWG criteria for PR: greater than or equal to (\>=) 50 percent (%) reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to less than (\<) 200 milligrams (mg)/24 hours, If the serum and urine M-proteins are not measurable, a decrease of \>=50% in the difference between involved and uninvolved free light chain (FLC) levels were required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay was also not measurable, \>=50% reduction in bone marrow plasma cells (PCs) was required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%. In addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas was also required.
| Percentage of participants | Daratumumab IV | Daratumumab SC |
|---|---|---|
| Overall Response Rate (ORR) | 39.4 (33.4 to 45.6) | 43.3 (37.3 to 49.6) |
Maximum Ctrough was defined as the serum predose concentration of daratumumab on Cycle 3 Day 1.
| micrograms per milliliter (mcg/mL) | Daratumumab IV | Daratumumab SC |
|---|---|---|
| Maximum Trough Concentration (Ctrough) of Daratumumab | 525 ± 227 | 611 ± 318 |
Percentage of participants with treatment-emergent infusion-related reactions were reported.
| Percentage of participants | Daratumumab IV | Daratumumab SC |
|---|---|---|
| Percentage of Participants With Treatment-emergent Infusion-related Reactions (IRR) | 34.5 (28.7 to 40.6) | 12.7 (8.9 to 17.4) |
PFS was defined as time from date of randomization to either progression of disease (PD), death due to any cause, whichever occurs first. IMWG criteria for PD: Increase of 25% from lowest response value in any one of the following: Serum M component (absolute increase must be \>=0.5 gram per deciliter (g/dL), Urine M-component (absolute increase must be \>=200 mg/24 hours), Participants without measurable serum and urine Mprotein levels: difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be \>10 milligrams per deciliter (mg/dL), participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow PC% (absolute percentage must be \>=10%), definite development of new bone lesions or soft tissue plasmacytomas or increase in size of bone lesions or tissue plasmacytomas and development of hypercalcemia (serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.
| Months | Daratumumab IV | Daratumumab SC |
|---|---|---|
| Progression Free Survival (PFS) | 6.08 (4.73 to 7.43) | 5.62 (4.70 to 7.49) |
VGPR or better was defined as the percentage of participants who achieved VGPR or better (VGPR, complete response (CR) or stringent complete response \[sCR\]), based on computerized algorithm as per IMWG criteria during or after the study treatment. IMWG criteria for VGPR: Serum and urine M-component detectable by immunofixation but not on electrophoresis, or \>=90 percent (%) reduction in serum M-protein plus urine M-protein \<100 milligrams (mg)/24 hours, CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells (PCs) in bone marrow. sCR: CR plus normal FLC ratio, and absence of clonal PCs by immunohistochemistry (IHC), immunofluorescencea or 2- to 4 color flow cytometry.
| Percentage of participants | Daratumumab IV | Daratumumab SC |
|---|---|---|
| Percentage of Participants With Very Good Partial Response (VGPR) or Better | 21.6 (16.8 to 27.1) | 23.6 (18.6 to 29.2) |
CR or better was defined as percentage of participants with a CR or better (CR or stringent complete response \[sCR\]) based on computerized algorithm as per IMWG criteria. IMWG criteria for CR- negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and \<5% PCs in bone marrow. sCR: CR plus normal FLC ratio, and absence of clonal PCs by IHC, immunofluorescencea or 2- to 4 color flow cytometry.
| Percentage of participants | Daratumumab IV | Daratumumab SC |
|---|---|---|
| Percentage of Participants With Complete Response (Including sCR) or Better | 5.4 (3.0 to 8.9) | 4.6 (2.4 to 7.8) |
Time to next therapy was defined as the time from randomization to the start of the first subsequent anti-cancer therapy.
| Months | Daratumumab IV | Daratumumab SC |
|---|---|---|
| Time to Next Therapy | 9.43 (8.15 to 10.71) | 8.80 (7.59 to 10.91) |
OS was defined as the time from the date of randomization to the date of the participant's death due to any cause.
| Months | Daratumumab IV | Daratumumab SC |
|---|---|---|
| Overall Survival (OS) | 25.56 (22.05 to NA) | 28.19 (22.77 to NA) |
Modified-CTSQ contain 9 items (2 items for Thoughts about Cancer Therapy and 7 items in a defined domain of Satisfaction with Therapy) specific to satisfaction with therapy and for comparison of SC and IV administration. Satisfaction with therapy was calculated based on 7-items using 5-point verbal rating scale, where 1= never and 5= always. Scores were averaged and transformed to a 0-100 scale; higher scores represent better health. At least 5 of the 7 items within the Satisfaction with Therapy domain had to be completed to calculate a domain score. No domain score was calculated for Thoughts about Cancer Therapy.
| Units on a scale | Daratumumab IV | Daratumumab SC |
|---|---|---|
| Cycle 1 Day 8 | 70.5 ± 15.98 | 76.9 ± 14.64 |
| Cycle 1 Day 15 | 72.1 ± 16.72 | 78.8 ± 14.95 |
| Cycle 1 Day 22 | 72.8 ± 16.20 | 78.7 ± 15.75 |
| Cycle 2 Day 1 | 74.2 ± 16.44 | 79.7 ± 16.58 |
| Cycle 2 Day 8 | 74.8 ± 15.57 | 80.1 ± 17.24 |
| Cycle 2 Day 15 | 74.3 ± 16.94 | 80.0 ± 17.37 |
| Cycle 2 Day 22 | 75.2 ± 16.47 | 79.3 ± 18.65 |
| Cycle 3 Day 1 | 76.0 ± 17.39 | 80.4 ± 17.78 |
| Cycle 4 Day 1 | 76.6 ± 17.22 | 79.5 ± 19.88 |
| Cycle 5 Day 1 | 77.1 ± 17.11 | 79.6 ± 18.95 |
| Cycle 6 Day 1 | 76.1 ± 17.79 | 81.9 ± 18.34 |
| Cycle 7 Day 1 | 78.6 ± 16.01 | 85.0 ± 16.87 |
| Cycle 8 Day 1 | 79.2 ± 15.54 | 85.0 ± 15.18 |
| Cycle 9 Day 1 | 79.8 ± 15.27 | 85.2 ± 15.03 |
| Cycle 10 Day 1 | 79.4 ± 14.73 | 85.8 ± 13.31 |
| Cycle 11 Day 1 | 79.1 ± 15.55 | 84.8 ± 13.50 |
| Cycle 12 Day 1 | 80.3 ± 15.88 | 85.4 ± 14.70 |
| Cycle 13 Day 1 | 79.6 ± 16.57 | 84.4 ± 15.09 |
| Cycle 14 Day 1 | 80.6 ± 14.62 | 83.5 ± 15.54 |
| Cycle 15 Day 1 | 80.2 ± 15.22 | 86.2 ± 13.51 |
| Cycle 16 Day 1 | 79.4 ± 14.84 | 88.5 ± 13.10 |
| Cycle 17 Day 1 | 79.0 ± 14.34 | 90.9 ± 11.26 |
| Cycle 18 Day 1 | 84.8 ± 14.13 | 91.4 ± 11.57 |
| Cycle 19 Day 1 | 92.9 ± 10.10 | 89.3 ± 13.36 |
| Cycle 20 Day 1 | — | 86.6 ± 18.53 |
| Cycle 21 Day 1 | — | 84.5 ± 20.93 |
| Cycle 22 Day 1 | — | 96.4 |
Duration of response was defined as the duration from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease according to the IMWG criteria. PD was defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M-component (absolute increase must be \>= 0.5 g/dL and \>=200 mg/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \> 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.
| Months | Daratumumab IV | Daratumumab SC |
|---|---|---|
| Duration of Response | 10.64 (9.23 to 15.64) | 10.15 (9.23 to 13.77) |
Time to PR or better was defined as the time from randomization until onset of first response of PR or better.
| Months | Daratumumab IV | Daratumumab SC |
|---|---|---|
| Time to Partial Response (PR) or Better | 1.02 (0.9 to 24.8) | 1.02 (0.9 to 9.4) |
Time to VGPR or better was defined as the time from randomization until onset of first VGPR or better.
| Months | Daratumumab IV | Daratumumab SC |
|---|---|---|
| Time to Very Good Partial Response (VGPR) or Better | 1.92 (0.9 to 22.8) | 1.95 (1.0 to 19.4) |
Time to CR or better was defined as the time from randomization until onset of first CR or better.
| months | Daratumumab IV | Daratumumab SC |
|---|---|---|
| Time to Complete Response (CR) or Better | 7.23 (1.1 to 14.9) | 9.26 (1.2 to 23.1) |
Collected over Up to 3 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Daratumumab IV | 130/258 (50.4%) | 89/258 (34.5%) | 216/258 (83.7%) |
| Daratumumab SC | 126/260 (48.5%) | 83/260 (31.9%) | 217/260 (83.5%) |
| Event | Daratumumab IV | Daratumumab SC |
|---|---|---|
| PneumoniaInfections and infestations | 13/258 | 12/260 |
| General Physical Health DeteriorationGeneral disorders | 6/258 | 4/260 |
| PyrexiaGeneral disorders | 6/258 | 4/260 |
| AnaemiaBlood and lymphatic system disorders | 4/258 | 6/260 |
| Lung InfectionInfections and infestations | 2/258 | 5/260 |
| Bone PainMusculoskeletal and connective tissue disorders | 3/258 | 5/260 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/258 | 3/260 |
| Lower Respiratory Tract InfectionInfections and infestations | 4/258 | 3/260 |
| SepsisInfections and infestations | 4/258 | 4/260 |
| Septic ShockInfections and infestations | 4/258 | 3/260 |
| Event | Daratumumab IV | Daratumumab SC |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 64/258 | 71/260 |
| NeutropeniaBlood and lymphatic system disorders | 34/258 | 52/260 |
| ThrombocytopeniaBlood and lymphatic system disorders | 50/258 | 49/260 |
| Upper Respiratory Tract InfectionInfections and infestations | 30/258 | 44/260 |
| DiarrhoeaGastrointestinal disorders | 32/258 | 41/260 |
| Back PainMusculoskeletal and connective tissue disorders | 36/258 | 31/260 |
| CoughRespiratory, thoracic and mediastinal disorders | 36/258 | 25/260 |
| PyrexiaGeneral disorders | 34/258 | 36/260 |
| FatigueGeneral disorders | 26/258 | 33/260 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 18/258 | 33/260 |
| Age, Continuous(years) | Daratumumab IV | Daratumumab SC | Total |
|---|---|---|---|
| Mean | 66.8 ± 10.16 | 65.3 ± 9.11 | 66.1 ± 9.66 |
| Sex: Female, Male(Participants) | Daratumumab IV | Daratumumab SC | Total |
|---|---|---|---|
| Female | 110 | 127 | 237 |
| Male | 149 | 136 | 285 |
| Ethnicity (NIH/OMB)(Participants) | Daratumumab IV | Daratumumab SC | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 14 | 23 |
| Not Hispanic or Latino | 227 | 225 | 452 |
| Unknown or Not Reported | 23 | 24 | 47 |
| Race (NIH/OMB)(Participants) | Daratumumab IV | Daratumumab SC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 40 | 32 | 72 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 5 | 9 | 14 |
| White | 201 | 207 | 408 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 12 | 14 | 26 |
| Region of Enrollment(Participants) | Daratumumab IV | Daratumumab SC | Total |
|---|---|---|---|
| AUSTRALIA | 15 | 13 | 28 |
| BRAZIL | 10 | 15 | 25 |
| CANADA | 16 | 20 | 36 |
| CZECH REPUBLIC | 20 | 16 | 36 |
| FRANCE | 6 | 10 | 16 |
| GREECE | 1 | 6 | 7 |
| ISRAEL | 5 | 8 | 13 |
| ITALY | 10 | 16 | 26 |
| JAPAN | 24 | 18 | 42 |
| POLAND | 39 | 26 | 65 |
| RUSSIAN FEDERATION | 28 | 27 | 55 |
| SOUTH KOREA | 7 | 4 | 11 |
| SPAIN | 14 | 12 | 26 |
| SWEDEN | 18 | 18 | 36 |
| TAIWAN | 6 | 8 | 14 |
| UKRAINE | 22 | 25 | 47 |
| UNITED KINGDOM | 16 | 17 | 33 |
| UNITED STATES | 2 | 4 | 6 |
| Stage of Disease (ISS)(Participants) | Daratumumab IV | Daratumumab SC | Total |
|---|---|---|---|
| Stage I | 94 | 82 | 176 |
| Stage II | 89 | 101 | 190 |
| Stage III | 76 | 79 | 155 |
| Data missing or Unknown | 0 | 1 | 1 |
| Number of prior lines(Participants) | Daratumumab IV | Daratumumab SC | Total |
|---|---|---|---|
| Less than or equal to (<=) 4 Lines | 175 | 174 | 349 |
| Greater than (>) 4 Lines | 84 | 89 | 173 |
| Refractory status(Participants) | Daratumumab IV | Daratumumab SC | Total |
|---|---|---|---|
| Both protease inhibitor (PI) and immunomodulatory drug (IMiD) | 133 | 125 | 258 |
| IMiD only | 81 | 67 | 148 |
| None | 26 | 41 | 67 |
| PI only | 19 | 30 | 49 |
1 further baseline measures are reported on the registry.
Showing the first 100 of 146 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2017 to primary completion in Jun 2019, 20 months.
Results were first posted in Jul 2020, 1 year 1 month after primary completion.
Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 20 months is below that.
Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daratumumab
Janssen Research & Development, LLC →